Skip to content
AnalystLens

Roivant Sciences 8-K Report, Regulation FD Disclosure (Dec 11, 2025)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed December 11, 2025
Period End
December 11, 2025
Security
ROIV
In the record · 2021–202610-K510-Q168-K82

ROIV filed 5 annual reports (10-K), 16 quarterly reports (10-Q) and 82 current reports (8-K) between 2021 and 2026.

  1. Leadership change8-K · Nov ’22Nov ’22
  2. Deal closed8-K · Dec ’23Dec ’23
  3. Leadership change8-K · Mar ’25Mar ’25

01—Abstract

Summary

Summary of the 8-K filed December 11, 2025. Cited figures are marked; the original filing is the authoritative source.

Roivant Sciences Ltd. (Nasdaq: ROIV) furnished this Form 8-K under Item 7.01 (Regulation FD) on December 11, 2025, in connection with its 2025 Investor Day.

The filing attaches a press release (Exhibit 99.1) and the Investor Day presentation (Exhibit 99.2). Both exhibits are furnished, not filed, for Section 18 purposes. The headline update is a set of accelerated timing guidance across four programs.

The brepocitinib NDA filing in dermatomyositis (DM) is now expected in early calendar 2026, with commercial launch expected early in calendar 2027. The Phase 3 CLARITY trial in non-infectious uveitis (NIU) is fully enrolled, with topline data now expected in the second half of calendar 2026, versus prior guidance of the first half of 2027. The brepocitinib proof-of-concept trial in cutaneous sarcoidosis (CS) is fully enrolled, with topline data now expected in the first half of 2026, versus prior guidance of the second half of 2026.

The IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) now has topline data expected in calendar 2026, previously expected as Period 1 data in 2026 and topline in 2027. Management also highlighted financial and strategic points. A Roivant-led financing at Immunovant generated gross proceeds to Immunovant of approximately $550 milliona, which the company says extends Immunovant's cash runway to the launch of IMVT-1402 in Graves' disease.

The presentation cites $4.4 billionb of cash, cash equivalents, restricted cash and marketable securities as of September 30, 2025, and a $1.5 billion share repurchase with an additional $500 million authorized. Management states that its cash balance supports runway into profitability and that all other pipeline programs remain on track.

02—Key points

Key Highlights

  1. Brepocitinib DM NDA filing now expected in early calendar 2026; launch expected early calendar 2027
  2. Brepocitinib Phase 3 NIU trial (CLARITY) fully enrolled; topline data now expected 2H 2026, versus prior guidance of 1H 2027
  3. Brepocitinib Phase 2 CS trial (BEACON) fully enrolled; topline data now expected 1H 2026, versus prior guidance of 2H 2026
  4. IMVT-1402 D2T RA potentially registrational trial topline data now expected in calendar 2026, versus prior Period 1 data in 2026 and topline in 2027
  5. Immunovant financing generated gross proceeds to Immunovant of approximately $550 million, extending its cash runway to the IMVT-1402 GD launch
  6. Roivant cites $4.4 billion of cash and marketable securities as of September 30, 2025, and a $1.5 billion buyback with an additional $500 million authorized
  7. Management targets 3+ launches, 4+ NDA/BLA filings, 8+ pivotal and 3+ proof-of-concept readouts over the next three years

03—Questions

Frequently Asked Questions

  1. What timing changes did Roivant announce for its key programs?

    Roivant accelerated guidance for several readouts. The brepocitinib CS proof-of-concept topline is now expected in 1H 2026 (previously 2H 2026), the brepocitinib NIU Phase 3 topline is now expected in 2H 2026 (previously 1H 2027), and the IMVT-1402 D2T RA topline is now expected in calendar 2026 (previously 2027). The DM NDA filing is now expected in early 2026 (previously 1H 2026).

  2. When is brepocitinib expected to launch in dermatomyositis?

    The presentation states that the brepocitinib NDA filing in DM is expected in early calendar 2026, with potential commercial launch early in calendar 2027. The filing also states that commercial preparation is underway.

  3. What did the Immunovant financing accomplish?

    The press release states that the Roivant-led Immunovant financing alongside key institutional investors generated gross proceeds to Immunovant of approximately $550 million. Roivant says this extends Immunovant's cash runway to the launch of IMVT-1402 in Graves' disease.

  4. How much cash does Roivant have and what capital returns has it made?

    The presentation cites $4.4 billion of cash, cash equivalents, restricted cash and marketable securities as of September 30, 2025, which it says funds the current pipeline into profitability. Roivant completed a $1.5 billion share repurchase and has authorized an additional $500 million. The presentation also notes approximately $2 billion available for late-stage development and high-value opportunities.

04—Continue

← View all 8-K filings